Multimodal Pharmacologic Strategies for Chronic Cancer Pain: A Systematic Review. (PubMed, Cureus) - Sep 22, 2026 - "In one trial, duloxetine was associated with clinically meaningful pain-response rates, although its primary mean pain-score analysis was not statistically significant. Low-dose gabapentin plus imipramine reduced pain and rescue-morphine use. Pregabalin reduced the morphine dose required to maintain pain control in one crossover trial, while other pregabalin studies showed numerical or non-significant benefits. Neither nabiximols trial met its primary efficacy endpoint, and nefopam did not significantly improve pain response or morphine consumption...Overall, the evidence remains heterogeneous and insufficient to support a standard multimodal pharmacological regimen. Selected antidepressant and gabapentinoid strategies, particularly in neuropathic cancer pain, may benefit selected patients."
Journal • Review • Addiction (Opioid and Alcohol) • Oncology • Pain
|
|
Amanda Squire; Ashique Ahamed; Richard Berman; Savannah Q Thirza
|